April 8 (Reuters) - Organon & Co :
* PHASE 3 COMPARATIVE CLINICAL STUDY OF PROLIA® AND XGEVA® (DENOSUMAB) BIOSIMILAR CANDIDATE HLX14 MET PRIMARY ENDPOINTS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
April 8 (Reuters) - Organon & Co :
* PHASE 3 COMPARATIVE CLINICAL STUDY OF PROLIA® AND XGEVA® (DENOSUMAB) BIOSIMILAR CANDIDATE HLX14 MET PRIMARY ENDPOINTS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Comments